Long Shortz with Racura: Lung cancer trial edges closer to patient enrolment
Long Shortz with Racura: Lung cancer trial edges closer to patient enrolment
Host Tylah Tully sits down with Racura Oncology (ASX:RAC) CEO Dr Daniel Tillett to discuss the company’s upcoming HARNESS-1 lung cancer trial. Watch the video here....
Pioneering Aussie biotechs pass the clinical test
Pioneering Aussie biotechs pass the clinical test
The performance of the ASX life sciences sector during the reporting season is a precautionary tale about not trusting statistics – or at least not relying on them at face value. Read article here...
Racura scientists develop cardioprotection blood test to support key trial
Racura scientists develop cardioprotection blood test to support key trial
Racura Oncology scientists have developed a novel blood-based molecular test designed to assess the cardioprotective effects of its lead drug candidate RC220. Read article here....
Long Shortz with Racura: Unlocking major IP and clinical milestones in transformative quarter
Long Shortz with Racura: Unlocking major IP and clinical milestones in transformative quarter
Host Tylah Tully sits down with Racura Oncology (ASX:RAC) executive director Peter Smith who talks through the company’s transformative quarter, marked by major intellectual property, clinical and funding milestones. Watch the interview here....
Proactive Investors: Race Oncology funds HARNESS-1 lung cancer trial
Proactive Investors: Race Oncology funds HARNESS-1 lung cancer trial
Race Oncology Ltd executive director and chairman Dr Peter Smith talked with Proactive about securing more than A$3.22 million via a private placement to fund the HARNESS-1 Phase 1a/b clinical trial. Read full article...
Stockhead: Racura Oncology gains ethics approval for HARNESS-1 lung cancer trial
Stockhead: Racura Oncology gains ethics approval for HARNESS-1 lung cancer trial
Special Report: Racura Oncology has taken a significant step forward in the clinical development of its next-generation cancer therapy RC220, receiving human ethics approval for a HARNESS-1 Phase 1a/b trial in patients with EGFR-mutated non-small...
The Australian: Racura Oncology targets two new cancer markets with RC220’s unique molecular action
The Australian: Racura Oncology targets two new cancer markets with RC220’s unique molecular action
Special Report: Racura Oncology has discovered the unique molecular mechanism of action for its RC220 therapy, opening two new major potential indications to explore in a clinical setting. Read full article here....
Proactive: Turning risk into advantage: Racura Oncology’s push to make chemotherapy safer
Proactive: Turning risk into advantage: Racura Oncology’s push to make chemotherapy safer
Proactive Investors covered Racura Oncology’s cardio-oncology strategy and the potential of RC220 to make anthracycline-based chemotherapy safer for patients. The article highlights progress in our international Phase 1 trial, our dual anticancer and cardioprotective...
The Australian: ASX Health Quarterly Wrap – Progress on multiple fronts in strong start to FY26
The Australian: ASX Health Quarterly Wrap – Progress on multiple fronts in strong start to FY26
Stockhead and The Australian included Racura Oncology in an ASX healthcare company quarterly results season wrap up, which highlights ongoing progress, including new discoveries and clinical trial updates to propel growth in FY26. The...
Long Shortz with Racura Oncology: Understanding the mechanism of action that could transform cancer therapy
Long Shortz with Racura Oncology: Understanding the mechanism of action that could transform cancer therapy
Racura Oncology CEO Dr Daniel Tillett spoke to Stockhead’s Tylah Tully to discuss the groundbreaking discovery of the primary mechanism of action of their lead drug. Dr Tillett explains how understanding the drug’s mechanism increases...
